Gilead and Kite Oncology Announce Cost-Effectiveness of Yescarta® in Large B-Cell Lymphoma in Singapore

14 June 2024 | Friday | News

New Data Presented at EHA Meeting Shows Yescarta® Offers Significant Quality of Life Benefits and Budget Impact Advantages Over Standard of Care for Relapsed LBCL Patients
Image Source : Public Domain

Image Source : Public Domain

Gilead and Kite Oncology announced new data from analyses of Yescarta® (axicabtagene ciloleucel), demonstrating its cost-effectiveness and budget impact compared to the current Standard of Care (SOC) in patients with large B-cell lymphoma (LBCL) who are refractory to or relapse within 12 months of first-line chemoimmunotherapy. These findings were presented at the European Hematology Association (EHA) meeting.

The analyses revealed several key points:

  • Quality Adjusted Life Years (QALYs) and Costs: In the base-case analysis over a lifetime horizon, Yescarta-treated patients generated 8.24 discounted QALYs, compared to 6.52 QALYs for SOC patients, resulting in an incremental QALY gain of 1.72.

  • Incremental Cost-Effectiveness Ratio (ICER): Compared to SOC, Yescarta demonstrated an ICER of S$75,910 (US$55,534) per QALY gained. This is below 1× GDP per capita of Singapore (S$113,779 [US$83,238] in 2023). According to the World Health Organization, a treatment strategy is considered highly cost-effective if the ICER is below 1× GDP per capita.

  • Budget Impact: Introducing Yescarta to Singapore’s public healthcare system for second-line LBCL is expected to increase the annual budget impact by approximately 17%, from S$21.7 million (US$15.9 million) without Yescarta to S$25.4 million (US$18.6 million) with Yescarta in Year 5, during which peak usage is expected. This increase is mitigated by a reduction in subsequent treatment-related costs by S$9.3 million/year (US$6.8 million/year), from S$17.1 million/year (US$12.5 million/year) to S$7.8 million/year (US$5.7 million/year) in Year 5.

Diego Santoro, General Manager of the Intercontinental Region at Kite, commented on the significance of these findings: “The analyses demonstrate the cost-effectiveness of Yescarta in second-line treatment from the perspective of Singapore’s public healthcare system compared to bone marrow transplant. This marks an important step towards providing patients in Singapore with the option of CAR T-cell therapy earlier in their treatment journey, allowing for a more cost-effective allocation of resources and a manageable budget impact.”

The standard of care (SOC) for treating DLBCL patients has historically involved a multi-step process that starts with chemoimmunotherapy, followed by high-dose chemotherapy (HDT), and culminates with a stem cell transplant (ASCT). While approximately 60% of newly diagnosed LBCL patients respond to initial chemotherapy, about 40% will relapse or not respond, necessitating second-line treatment


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in